Over at the California Stem Cell Report, David Jensen is reporting on some good news from CIRM for California on the stem cell medical trial front.
Stem cell biotechs Asterias and Capricor have stem cell trials supported simply by 20+ million in CIRM funding each and have already been hitting milestones. These trials are progressing and so considerably have good safety profiles. Asterias and CIRM have got mentioned some possibly encouraging early hints at efficacy too in its trial, and apparently there are hopeful hints from your Capricor trial too.
View the posts from CIRM here (a weekly summary kind of post that begins talking about Asterias) and here . Just for background, also see past posts I’ ve accomplished on both companies here and here in the archives, and see specifically my interview with Asterias leadership from a few months back.
It’ ersus early days for these trials and at these phases they are not actually designed to look for efficacy so a conservative approach to talking about such trials is in order given the stage, yet at this phase of the game for early clinical tests the news has been all one could hope for so far both in cases.
The Asterias plus Capricor trials are for spinal cord injury and Duchenne muscular dystrophy, respectively. The latter trial utilizes the Capricor CAP-1002 product, which is a cool allogeneic cardiosphere technology manufactured from donor human heart tissue. A beating cardiosphere from a various source (IPSCs) can be seen in the video above. Asterias’ demo employs their OPC product made from hESCs, which is also innately allogeneic. The idea of potentially repairing the injured spine through stem cells is intriguing.
I’ mirielle hoping in the next month or so to do a broader upgrade on the stem cell and regenerative medicine biotech area. By way of disclosure, I do not have any financial stake in possibly company discussed here.